Antithrombotic therapy in cardiac stent patients
- 26 Downloads
The use of coronary stents has made a significant impact on immediate angiographic results of coronary angioplasty as well as on the more important incidence of restenosis and the need for repeat procedures. This could not have been accomplished without adjuvant antithrombotic therapy directed predominantly at platelet function. Antiplatelet agents have significantly reduced the complications and improved the long-term outcome following coronary stent placement. This paper reviews the evolution of adjuvant antithrombotic therapy following stent placement, the agents currently used and future directions being investigated.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 1.Topol EJ, Mark DB, Lincoff AM, et al.: Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Lancet 1999, 354:2019–2024. One-year follow-up of the largest randomized trial of coronary stent implantation evaluating the concomitant use of abciximab therapy. The abciximab arm had a lower overall mortality and in diabetics the incidence of target vessel revascularization was less.PubMedCrossRefGoogle Scholar
- 10.Bertrand ME, Legrand V, Boland J, et al.: Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 1998, 98:1597–1603.PubMedGoogle Scholar
- 26.Schomig A, Kastrati A, Dirschinger J, et al.: for the Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators: Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. N Engl J Med 2000, 343:385–391.PubMedCrossRefGoogle Scholar
- 28.Tcheng JE: High dose eptifibatide in elective coronary stenting. Results of the ESPRIT trial. Presented at the 49th Annual Scientific Meetings of the American College of Cardiolgy. Anaheim, CA: March 12–15, 2000.Google Scholar
- 30.Kereiakes DJ, Kleiman NS, Ferguson JJ, et al.: Pharmacodynamic efficiency, clinical safety, and outcomes after prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter placebo-controlled, randomized trial. Circulation 1998, 98:1268–1278.PubMedGoogle Scholar